Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunomodulation as asthma therapy: where do we stand?

P J Barnes1

  • 1Dept of Thoracic Medicine, National Heart and Lung Institute, London, UK.

The European Respiratory Journal. Supplement
|August 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glucocorticoid resistance in asthma.

American journal of respiratory and critical care medicine·1995
Same author

Abnormal glucocorticoid receptor-activator protein 1 interaction in steroid-resistant asthma.

The Journal of experimental medicine·1995
Same author

Inhibition of macrophage inflammatory protein-1 alpha expression by IL-10. Differential sensitivities in human blood monocytes and alveolar macrophages.

Journal of immunology (Baltimore, Md. : 1950)·1995
Same author

Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.

Molecular pharmacology·1995
Same author

Corticosteroid inhibition of macrophage inflammatory protein-1 alpha in human monocytes and alveolar macrophages.

The American journal of physiology·1995
Same author

Cytokine expression in normal, atopic, and asthmatic subjects using the combination of sputum induction and the polymerase chain reaction.

Thorax·1995
Same journal

Current status of lung transplantation.

The European respiratory journal. Supplement·2003
Same journal

Treatment of chronic respiratory failure: lung volume reduction surgery versus rehabilitation.

The European respiratory journal. Supplement·2003
Same journal

Home ventilation.

The European respiratory journal. Supplement·2003
Same journal

Mechanical ventilation: invasive versus noninvasive.

The European respiratory journal. Supplement·2003
Same journal

Respiratory failure in chronic obstructive pulmonary disease.

The European respiratory journal. Supplement·2003
Same journal

Physical and biological triggers of ventilator-induced lung injury and its prevention.

The European respiratory journal. Supplement·2003
See all related articles

Chronic asthma inflammation involves type 2 T-helper (Th2) cytokines. Targeted immunomodulators, like interleukin-5 (IL-5) inhibitors, offer potential asthma control with reduced toxicity compared to current treatments.

Area of Science:

  • Immunology
  • Pulmonology
  • Pharmacology

Background:

  • Chronic asthma is characterized by airway inflammation mediated by cytokines from various cells.
  • Type 2 T-helper (Th2) lymphocytes play a key role in orchestrating eosinophilic inflammation in asthma.
  • Current treatments like glucocorticoids suppress Th2-derived cytokines such as interleukin-5 (IL-5).

Purpose of the Study:

  • To explore the role of cytokine networks in asthma-related chronic inflammation.
  • To evaluate the potential of immunomodulatory agents for asthma control.
  • To identify selective immunomodulators with improved safety profiles for asthma management.

Main Methods:

  • Review of evidence on cytokine involvement in asthma pathogenesis.
  • Analysis of the mechanisms of action of existing and potential immunomodulatory drugs.

Related Experiment Videos

  • Discussion of selective delivery methods and targeted cellular effects for future therapies.

    • Main Results:

    • Glucocorticoids may exert their anti-asthma effects by suppressing Th2-derived cytokines like IL-5.
    • Cyclosporin-A shows immunomodulatory potential but is limited by parenteral toxicity.
    • Selective immunomodulators are needed for improved asthma control.

    Conclusions:

    • Future asthma therapies should focus on selective immunomodulation targeting Th2 pathways.
    • Potential strategies include targeted delivery, specific cytokine inhibition (e.g., IL-5 antibodies), and novel agents like mycophenolate mofetil or PDE4 inhibitors.
    • Developing safer and more effective immunomodulators is crucial for managing chronic asthma.